PALVELLA THERAPEUTICS, INC
NASDAQ: PVLA (Palvella Therapeutics, Inc.)
Last update: yesterday, 9:47AM142.85
-2.92 (-2.00%)
| Previous Close | 145.77 |
| Volume | 192,670 |
| Avg. Volume (3M) | 240,407 |
| Market Cap | 2,088,246,656 |
| Price / Book | 10.82 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Diluted EPS (TTM) | -5.53 |
| Total Debt/Equity (MRQ) | 12.84% |
| Current Ratio (MRQ) | 16.01 |
| Operating Cash Flow (TTM) | -43.06 M |
| Levered Free Cash Flow (TTM) | -27.99 M |
| Return on Assets (TTM) | -28.68% |
| Return on Equity (TTM) | -63.39% |
News Mood
-
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)
3 days ago, 6:30AM
-
Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
05 Nov, 5:16PM
-
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
05 Nov, 4:14PM
AIStockmoo Score
| Value 30% | 0.0 |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 1.3 |
| No clear trend over the past year. Somewhat below its 52-week high. info | |
| In an uptrend: the price is above its moving averages, and they are rising. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Sentiment 20% | 0.5 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 1.6 |
| No clear net insider buying or selling. info | |
| Institutions net +8.08% of shares in their latest 13F filings: 120 holders increased, 80 decreased (quarter to 30 Sep 2026). info | |
| Short interest +13.5% from 31 Aug to 30 Oct 2026, 11.5 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Earnings per share have gone up and down. Made a loss in recent years. info | |
| Recent bullish reversal pattern: Inverted hammer, Bullish engulfing. info | |
| Above its medium-term trend line. info | |
| Price is high against its 52-week average. Down over 5 years. info | |
| Short-term momentum fading. info | |
| Price is near support. info | |
| Final Score | 0.85 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Palvella Therapeutics, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
| GPCR | 1 B | - | - | 1.01 | -0.8 |
Select this tab to load the latest available analysis.
|
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 11.05% |
| % Held by Institutions | 105.08% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MARTINI JEFFREY S | - | 166.33 | -12,500 | -2,079,063 |
| Aggregate Net Quantity | -12,500 | |||
| Aggregate Net Value ($) | -2,079,063 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 166.33 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MARTINI JEFFREY S | Officer | 11 Nov 2026 | Automatic sell (-) | 6,250 | 163.94 | 1,024,625 |
| MARTINI JEFFREY S | Officer | 11 Nov 2026 | Option execute | 6,250 | - | - |
| MARTINI JEFFREY S | Officer | 10 Nov 2026 | Automatic sell (-) | 6,250 | 168.71 | 1,054,438 |
| MARTINI JEFFREY S | Officer | 10 Nov 2026 | Option execute | 6,250 | - | - |
Institutions
Institutional ownership: 103.74%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 120 | 2,170,153 |
| Decreased | 80 | 1,570,653 |
| New | 37 | 905,228 |
| Sold out | 27 | 292,038 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 2,601,661 | 11.5 |
| 15 Oct 2026 | 2,407,482 | 9.8 |
| 30 Sep 2026 | 2,524,140 | 10.7 |
| 15 Sep 2026 | 2,325,699 | 12.8 |
| 31 Aug 2026 | 2,291,288 | 11.1 |
| 14 Aug 2026 | 2,149,544 | 12.8 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 19 Nov 2026 | Yahoo Finance |
Palvella Therapeutics (PVLA) Stock Looks Above Fair Value After 51% Gain
Palvella Therapeutics has logged a strong 51.3% share price gain over the past year, which puts fresh attention on whether that move lines up with what its balance sheet actually supports. With traders also reacting to new product news, the question is how firmly the current valuation rests on… |
| 19 Nov 2026 | Yahoo Finance |
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)
EMPD is a serious, rare, and life-threatening genital and perianal skin cancer QTORIN™ docetaxel builds on human clinical evidence of I.V. docetaxel in EMPD, with the potential to shift the treatment paradigm to first-line, localized topical therapy QTORIN™ docetaxel has the potential to be the… |
| 19 Nov 2026 | Yahoo Finance |
Is Palvella Therapeutics (PVLA) Undervalued On Its New QTORIN Webcast Plans?
Palvella Therapeutics (PVLA) is back in focus after the company scheduled a November 19 webcast to introduce a new QTORIN program, the third drug candidate from its QTORIN platform for rare skin conditions. Palvella Therapeutics shares closed at $146.58, with a 1-day share price return of 1.54%.… |
| 18 Nov 2026 | Yahoo Finance |
Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program
Third product candidate from Palvella’s QTORIN™ platform to be announced Live audiovisual webcast to take place tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET WAYNE, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a… |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
Palvella Therapeutics Inc (PVLA) advances its Qtorin rapamycin NDA toward a February 2027 PDUFA date while funding a standalone U.S. launch and a deep pipeline of first-in-disease programs. |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Palvella Therapeutics, Inc.'s Q3 2026 earnings call… |
| 05 Nov 2026 | Yahoo Finance |
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential U.S. launch of QTORIN rapamycin after the Food and Drug Administration accepted its application for the treatment of microcystic lymphatic malformations and granted it Priority Review. The FDA set a target action date of February 28,… |
| 05 Nov 2026 | Yahoo Finance |
Palvella (PVLA) Q3 2026 Earnings Call Transcript
QTORIN rapamycin wins priority FDA review for a rare vascular disease. |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics: Q3 Earnings Snapshot
(AP) — Palvella Therapeutics, Inc. (PVLA) on Thursday reported a loss of $24… |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027 QTORIN™ Rapamycin Could Become the First FDA-Approved Therapy for Microcystic Lymphatic Malformations, a Serious, Rare Lifelong Disease… |
| 03 Nov 2026 | Yahoo Finance |
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
WAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no… |
| 29 Oct 2026 | Yahoo Finance |
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
WAYNE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no… |
| 28 Oct 2026 | Yahoo Finance |
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and adults in the U.S. Phase 3 SELVA study achieved highly statistically significant results across all… |
| 25 Oct 2026 | Yahoo Finance |
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said during a Chardan investor session. Korenberg said the company has expanded from deve… |
| 24 Oct 2026 | Yahoo Finance |
What Does Palvella Therapeutics (PVLA) NDA Progress Mean After Its Phase 3 Data?
Palvella Therapeutics (NasdaqGM:PVLA) reported positive Phase 3 SELVA trial results for QTORIN rapamycin in microcystic lymphatic malformations. The company has completed an FDA New Drug Application for QTORIN rapamycin following the SELVA efficacy and safety findings. Management also released new… |
| 22 Oct 2026 | Yahoo Finance |
Ligand to Host Investor Day on December 8, 2026
JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY… |
| 21 Oct 2026 | Yahoo Finance |
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering. |
| 15 Oct 2026 | Yahoo Finance |
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding Phase 2 TOIVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and Reductions in Lesion Bleeding in… |
| 13 Oct 2026 | Yahoo Finance |
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no… |
| 12 Oct 2026 | Yahoo Finance |
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours Comprehensive Real-World… |
| 28 Sep 2026 | Yahoo Finance |
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric… |
| 09 Sep 2026 | Yahoo Finance |
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and… |
| 02 Sep 2026 | Yahoo Finance |
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are… |
| 31 Aug 2026 | Yahoo Finance |
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S. FDA previously granted Breakthrough Therapy and Fast Track… |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |